S. Rösel

发表

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

Y. Ko, P. Wernet, R. Souchon, 2005, The Lancet.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study

S. Loibl, N. Harbeck, V. Nekljudova, 2013, Journal of Cancer Research and Clinical Oncology.

Oral vinorelbine for the treatment of breast cancer and non-small cell lung carcinoma in clinical practice

H. Bischoff, S. Rösel, 2015 .

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

T. Decker, T. Trarbach, M. Indorf, 2017, BMC Cancer.

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

H. Tesch, W. Jonat, V. Heinemann, 2011, British Journal of Cancer.

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

T. Decker, T. Trarbach, M. Indorf, 2017, BMC Cancer.

Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial: Results of a retrospective study

W. Eiermann, C. Jackisch, A. Rody, 2003 .

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

H. Tesch, W. Brugger, W. Freier, 2011, British Journal of Cancer.